Want to see ZYBT full AI Analyst Report?
ZYBT Stock Chart & Stats
$1.13
--
Market closed
$1.13
--
Day’s Range― - ―
52-Week Range$0.62 - $13.08
Previous CloseN/A
VolumeN/A
Average Volume (3M)871.70K
Market Cap
$53.50M
Enterprise Value$272.93M
Total Cash (Recent Filing)$51.89M
Total Debt (Recent Filing)$75.08M
Price to Earnings (P/E)―
Beta-0.39
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding10,965,000
10 Day Avg. Volume198,467
30 Day Avg. Volume871,704
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.52
Price to Sales (P/S)3.27
P/FCF Ratio541.63
Enterprise Value/Market Cap5.10
Enterprise Value/Revenue3.41
Enterprise Value/Gross Profit41.08
Enterprise Value/Ebitda-6.59
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Vertical Integration & GMP CapacityOwning end-to-end GMP-compliant production and development facilities supports consistent quality, lower outsourcing risk, and faster scale-up of vaccines. This structural capability improves supply reliability and long-term margins versus peers reliant on contract manufacturers.
Product Breadth & Export MarketsA broad portfolio (~50 animal vaccine products) and exposure to multiple export markets diversifies revenue sources and reduces single-market dependency. Durable product breadth supports cross-selling, resilience to localized demand shocks, and long-term growth optionality in multiple emerging markets.
Moderate Leverage And Sizable EquityA modest debt-to-equity (~0.30) and substantial equity provide balance-sheet flexibility to fund operations or capex without heavy refinancing risk. This cushion matters during cyclical revenue pressure and supports investment in capacity or regulatory compliance over the medium term.
Bears Say
Sustained Revenue DeclineA large, multi-year revenue contraction culminating in a sharp drop in 2025 signals structural demand, pricing, or market-share weakness. Persistent top-line erosion undermines scale economics, makes recovery of fixed-cost absorption harder, and raises execution risk for medium-term forecasts.
Profitability CollapseA swing from modest profitability to a severe net loss reflects either one-time shocks or deep structural margin pressure from lower volumes, pricing, or cost overruns. Persistently negative margins would erode retained capital and limit reinvestment or R&D over the medium term.
Weak Cash Generation & Thin FCFOperating cash flow materially weakened and free cash flow is effectively negligible, reducing self-funded investment capacity. Thin, volatile cash conversion increases dependency on external financing and constrains ability to weather prolonged revenue weakness or fund strategic initiatives.
Zhengye Biotechnology Holding Ltd. News
ZYBT FAQ
What was Zhengye Biotechnology Holding Ltd.’s price range in the past 12 months?
Zhengye Biotechnology Holding Ltd. lowest stock price was $0.61 and its highest was $13.08 in the past 12 months.
What is Zhengye Biotechnology Holding Ltd.’s market cap?
Zhengye Biotechnology Holding Ltd.’s market cap is $53.50M.
When is Zhengye Biotechnology Holding Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Zhengye Biotechnology Holding Ltd.’s earnings last quarter?
Currently, no data Available
Is Zhengye Biotechnology Holding Ltd. overvalued?
According to Wall Street analysts Zhengye Biotechnology Holding Ltd.’s price is currently Overvalued.
Does Zhengye Biotechnology Holding Ltd. pay dividends?
Zhengye Biotechnology Holding Ltd. does not currently pay dividends.
What is Zhengye Biotechnology Holding Ltd.’s EPS estimate?
Zhengye Biotechnology Holding Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zhengye Biotechnology Holding Ltd. have?
Zhengye Biotechnology Holding Ltd. has 10,965,000 shares outstanding.
What happened to Zhengye Biotechnology Holding Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Zhengye Biotechnology Holding Ltd.?
Currently, no hedge funds are holding shares in ZYBT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zhengye Biotechnology Holding Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-7.57%
Trailing 12-Months
Company Description
Zhengye Biotechnology Holding Ltd.
Zhengye Biotechnology Holding Limited specializes in the creation, manufacturing, and commercialization of animal health immunizations. The company primarily supplies the Chinese agricultural sector with vaccines tailored for a broad spectrum of farm animals, including swine, bovines, goats, ovines, and poultry. Additionally, its product range encompasses inoculations for canines. Beyond its domestic reach, the firm also distributes its offerings to international markets, notably exporting to Vietnam, Pakistan, and Egypt. Established in 2004, this enterprise bases its principal operations in Jilin, China, and operates as a subsidiary entity of Securingium Holding Limited.
Technical Analysis
China Pharma Holdings
―
China SXT Pharmaceuticals
―
Qilian International Holding Group Limited
―
Universe Pharmaceuticals
―
Shuttle Pharmaceuticals Holdings, Inc.
―
Ownership Overview
―
Insiders
0.27% Mutual Funds
0.12% Other Institutional Investors
99.62% Public Companies and
Individual Investors